Download PDF
Der Nuklearmediziner 2005; 28(1): 4-10
DOI: 10.1055/s-2005-836341
Labor, Radiochemie und (Radio-)Immunologie

© Georg Thieme Verlag Stuttgart · New York

Bestimmung von Kalzitonin

Determination of CalcitoninR. Görges1
  • 1Klinik für Nuklearmedizin, Klinikum Essen, Universität Duisburg/Essen und Gemeinschaftspraxis für Nuklearmedizin, Duisburg
Further Information

Publication History

Publication Date:
17 March 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Kalzitonin ist ein vergleichsweise sensitiver, spezifischer und reliabler Tumormarker, der bei der Primärdiagnostik und Nachsorge des C-Zellkarzinoms sowie der neoplastischen C-Zell-Hyperplasie einen zentralen Stellenwert besitzt. Wesentlich seltener wird Kalzitonin auch bei anderen Tumorarten nachgewiesen. Zur Messung sollten immunometrische Two-Site-Assays mit einer funktionellen Sensitivität um 1-2 pg/ml verwendet werden. Assays mit weitgehend selektiver Erfassung der monomeren Kalzitoninform bieten den Vorteil einer höheren Spezifität bezüglich des Erkennens von C-Zellkarzinomen. Unter diesen Voraussetzungen besitzen bereits Messungen des basalen Kalzitonins eine hohe diagnostische Aussagekraft. Die Durchführung eines Pentagastrintests kann die diagnostische Sensitivität und Spezifität der Kalzitoninbestimmung steigern, aber falsch positive Ergebnisse sind auch hierbei insbesondere bei C-Zellhyperplasie und Niereninsuffizienz von klinischer Relevanz. Bezüglich des Screenings der Familienmitglieder von Patienten mit C-Zellkarzinom hat die molekulargenetische Diagnostik in den letzten Jahren den Pentagastrintest weitgehend abgelöst. Als neues Einsatzgebiet rückt derzeit das Kalzitoninscreening bei Struma nodosa stärker in den Blickpunkt. Zwar können hierdurch nur bis 10 % der (ohnehin seltenen) Schilddrüsenmalignome erfasst werden, und bei den empfohlenen Interventionsschwellenwerten wird ein nicht unerheblicher Anteil unnötiger Schilddrüsenoperationen verursacht, aber die Chance kurativer Interventionen durch Erfassung früher Tumorstadien steigt.

Abstract

Calcitonin in serum is a comparatively highly sensitive, specific and reliable tumor marker of central relevance for the diagnosis and follow-up of medullary thyroidal C-cell carcinoma (MTC) and neoplastic C-cell hyperplasia (CCH). It is seen considerably less often in other tumor entities. For determination we recommend immunometric two-site assays of approximately 1-2 pg/ml sensitivity. Higher MTC specificity is achieved by assays focussing on a largely selective determination of monomeric calcitonin. If this is realized, basal calcitonin levels are already greatly relevant for MTC or CCH diagnosis. The diagnostic sensitivity and specificity of calcitonin determination may be further enhanced by means of pentagastrin test, but even then false positive results are clinically relevant especially in benign CCH and renal insufficiency. In family screening in case of MTC patients, moleculargenetic techniques have become the procedure of choice and have now largely replaced the pentagastrin test. Calcitonin screening in adenomatous goitre (struma nodosa) is making headway. Although this accounts for only 10 % of thyroidal malignomas (which are in fact rare), and the recommanded levels of intervention will result in many unnecessary surgical operations, early tumor staging definitely increases the chances for curative intervention.

Schlüsselwörter

Kalzitonin - Pentagastrintest - C-Zellkarzinom - Struma nodosa - Screening - Monomer

Key words

Calcitonin - pentagastrin test - medullary thyroid carcinoma - adenomatous goitre - screening - monomer

Literatur

  • 1 Barbot N, Calmettes C, Schuffenecker I, Saint-Andre J P, Franc B, Rohmer V, Jallet P, Bigorgne J C. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.  J Clin Endocrinol Metab. 1994;  78 114-120
    CrossrefPubMedSearch in Google Scholar
  • 2 Becker K L, Nash D, Silva O L, Snider R H, Moore C F. Increased serum and urinary calcitonin levels in patients with pulmonary disease.  Chest. 1981;  79 211-216
    PubMedSearch in Google Scholar
  • 3 Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid K W, Broelsch C E. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.  Thyroid. 2004;  14 468-470
    CrossrefPubMedSearch in Google Scholar
  • 4 Body J J, Chanoine J P, Dumon J C, Delange F. Circulating calcitonin levels in healthy children and subjects with congenital hypothyroidism from birth to adolescence.  J Clin Endocrinol Metab. 1993;  77 565-567
    CrossrefPubMedSearch in Google Scholar
  • 5 Borges M F, Abelin N M, Menezes F O, Dahia P L, Toledo S P. Calcitonin deficiency in early stages of chronic autoimmune thyroiditis.  Clin Endocrinol (Oxf). 1998;  49 69-75
    CrossrefPubMedSearch in Google Scholar
  • 6 Brauckhoff M, Gimm O, Brauckhoff K, Ukkat J, Thomusch O, Dralle H. Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma.  Langenbecks Arch Surg. 2001;  386 434-439
    CrossrefPubMedSearch in Google Scholar
  • 7 Conte N, Roiter I, Monco M A, Carniato A. Plasma immunoreactive calcitonin in acute and chronic lung diseases.  Minerva Endocrinol. 1984;  9 359-361
    PubMedSearch in Google Scholar
  • 8 Cohen R, Modigliani E. Medullary thyroid carcinoma: 25 years on.  The Cancer Journal. 1993;  6 59-64
    PubMedSearch in Google Scholar
  • 9 Copp D H, Cameron E C. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract.  Science. 1961;  134 2038
    PubMedSearch in Google Scholar
  • 10 Dietlein M, Dressler J, Grünwald F, Joseph K, Leisner B, Moser E, Reiners C, Rendl J, Schicha H, Schneider P, Schober O. Leitlinie zur Schilddrüsendiagnostik (Version 2).  Nuklearmedizin. 2003;  43 109-115
    PubMedSearch in Google Scholar
  • 11 Dietlein M, Moka D, Schmidt M, Theissen P, Schicha H. Prävention, Screening and Therapie gutartiger Schilddrüsenerkrankungen unter dem Aspekt von Kosten und Nutzen.  Nuklearmedizin. 2003;  42 181-189
    PubMedSearch in Google Scholar
  • 12 Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10 864 patients with nodular thyroid disorders.  J Clin Endocrinol Metab. 2004;  89 163-168
    CrossrefPubMedSearch in Google Scholar
  • 13 Engelbach M, Görges R, Forst T, Pfutzner A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements.  J Clin Endocrinol Metab. 2000;  85 1890-1894
    CrossrefPubMedSearch in Google Scholar
  • 14 Engelbach M, Heerdt S, Gorges R, Kunt T, Pfutzner A, Forst T, Diefenbach K, Walgenbach S, Beyer J. Is there an ectopic secretion of monomeric calcitonin in the human being?.  Langenbecks Arch Surg. 1998;  383 456-459
    CrossrefPubMedSearch in Google Scholar
  • 15 Erdogan M F, Gullu S, Baskal N, Uysal A R, Kamel N, Erdogan G. Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma.  J Clin Endocrinol Metab. 1997;  82 897-899
    CrossrefPubMedSearch in Google Scholar
  • 16 Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, Krivitzky A, Modigliani E.. French Medullary Study Group (GETC) . Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.  Clin Endocrinol (Oxf). 2001;  55 403-409
    CrossrefPubMedSearch in Google Scholar
  • 17 Frank-Raue K, Raue F, Buhr H J, Baldauf G, Lorenz D, Ziegler R. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization.  Thyroid. 1992;  2 113-117
    PubMedSearch in Google Scholar
  • 18 Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.  World J Surg. 1998;  22 562-567
    CrossrefPubMedSearch in Google Scholar
  • 19 Görges R. The changing epidemiology of thyroid cancer. In: Biersack HJ, Grünwald F (eds). Thyroid cancer. Springer, Berlin, Heidelberg 2001
  • 20 Grauer A, Raue F, Ziegler R. Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin.  Exp Clin Endocrinol Diabetes. 1998;  106 353-359
    PubMedSearch in Google Scholar
  • 21 Guyetant S, Wion-Barbot N, Rousselet M C, Franc B, Bigorgne J C, Saint-Andre J P. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases.  Hum Pathol. 1994;  25 514-521
    CrossrefPubMedSearch in Google Scholar
  • 22 Hadjadj S, Nunez S, Bohme P, Goulet Salmon B, Klein M, Weryha G, Leclere J. False elevated serum level of circulating calcitonin induced by omeprazole.  Presse Med. 1997;  26 1859
    PubMedSearch in Google Scholar
  • 23 Henriksen J H, Schifter S, Moller S, Bendtsen F. Increased circulating calcitonin in cirrhosis. Relation to severity of disease and calcitonin gene-related peptide.  Metabolism. 2000;  49 47-52
    CrossrefPubMedSearch in Google Scholar
  • 24 Hernandez G, Simo R, Oriola J, Mesa J. False-positive results of basal and pentagastrin-stimulated calcitonin in non-gene carriers of multiple endocrine neoplasia type 2 A.  Thyroid. 1997;  7 51-54
    PubMedSearch in Google Scholar
  • 25 Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hüfner M, Niederle B, Brabant G.. German Society for Endocrinology (DGE) - Thyroid Section . Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation.  Exp Clin Endocrinol Diabetes. 2004;  112 52-58
    Thieme ConnectPubMedSearch in Google Scholar
  • 26 Kebebew E, Ituarte P H, Siperstein A E, Duh Q Y, Clark O H. Related Articles, Links Abstract Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.  Cancer. 2000;  88 1139-1148
    CrossrefPubMedSearch in Google Scholar
  • 27 Kotzmann H, Schmidt A, Scheuba C, Kaserer K, Watschinger B, Soregi G, Niederle B, Vierhapper H. Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma.  Thyroid. 1999;  9 943-947
    CrossrefPubMedSearch in Google Scholar
  • 28 Lind L, Bucht E, Ljunghall S. Pronounced elevation in circulating calcitonin in critical care patients is related to the severity of illness and survival.  Intensive Care Med. 1995;  21 63-66
    CrossrefPubMedSearch in Google Scholar
  • 29 Lissak B, Baudin E, Cohen R, Barbot N, Meyrier A, Niccoli P, Bouyge N, Modigliani E. Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin.  Thyroid. 1998;  8 265-268
    CrossrefPubMedSearch in Google Scholar
  • 30 Marsh D J, McDowall D, Hyland V J, Andrew S D, Schnitzler M, Gaskin E L, Nevell D F, Diamond T, Delbridge L, Clifton-Bligh P, Robinson B G. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2 A families.  Clin Endocrinol (Oxf). 1996;  44 213-220
    CrossrefPubMedSearch in Google Scholar
  • 31 Marrinan M, Skrabanek P, Moriarty M, McPartlin J, Powell D. Hypercalcitoninaemia in medullary carcinoma of the thyroid and other malignancies: value of calcitonin as tumour marker.  Horm Metab Res. 1982;  14 213-215
    Thieme ConnectPubMedSearch in Google Scholar
  • 32 Martinetti A, Seregni E, Ferrari L, Pallotti F, Aliberti G, Coliva A, Fracassi S, Bombardieri E. Evaluation of circulating calcitonin: analytical aspects.  Tumori. 2003;  89 566-568
    PubMedSearch in Google Scholar
  • 33 Mendelsohn G, Wells Jr S A, Baylin S B. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease.  Cancer. 1984;  54 657-662
    PubMedSearch in Google Scholar
  • 34 Modigliani E, Cohen R, Campos J M,. et al . Prognostic factors for survival and biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group.  Clin Endocrinol (Oxf). 1998;  48 265-273
    CrossrefPubMedSearch in Google Scholar
  • 35 Niccoli P, Brunet P, Roubicek C, Roux F, Baudin E, Lejeune P J, Berland Y, Conte-Devolx B. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis.  Eur J Endocrinol. 1995;  132 75-81
    PubMedSearch in Google Scholar
  • 36 Oishi S, Shimada T, Tajiri J, Inoue J, Sato T. Elevated serum calcitonin levels in patients with thyroid disorders.  Acta Endocrinol (Copenh). 1984;  107 476-481
    PubMedSearch in Google Scholar
  • 37 Pedrazzoni M, Ciotti G, Davoli L, Pioli G, Girasole G, Palummeri E, Passeri M. Meal-stimulated gastrin release and calcitonin secretion.  J Endocrinol Invest. 1989;  12 409-412
    PubMedSearch in Google Scholar
  • 38 Poppe K, Verbruggen L A, Velkeniers B, Finne E, Body J J, Vanhaelst L. Calcitonin reserve in different stages of atrophic autoimmune thyroiditis.  Thyroid. 1999;  9 1211-1214
    CrossrefPubMedSearch in Google Scholar
  • 39 Raue F. German MTC/MEN Study Group . German medullary thyroid carcinoma/multiple endocrine neoplasia registry.  Langenbecks Arch Surg. 1998;  383 334-336
    CrossrefPubMedSearch in Google Scholar
  • 40 Redding A H, Levine S N, Fowler M R. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses.  Thyroid. 2000;  10 919-922
    PubMedSearch in Google Scholar
  • 41 Saeger H D, Pistorius S, Fitze G, Schackert H K. Prädiktive Medizin für das operative Fach.  Deutsches Ärzteblatt. 2002;  99 441
    PubMedSearch in Google Scholar
  • 42 Sagulin G B, Bucht E, Gilljam H, Sjoberg H, Roomans G M. Plasma calcitonin levels in patients with cystic fibrosis.  Res Commun Chem Pathol Pharmacol. 1990;  69 325-334
    PubMedSearch in Google Scholar
  • 43 Saller B, Görges R, Reinhardt W, Haupt K, Janssen O E, Mann K. Sensitive calcitonin measurement by two-site immunometric assays: implications for calcitonin screening in nodular thyroid disease.  Clin Lab. 2002;  48 191-200
    PubMedSearch in Google Scholar
  • 44 Saller B, Moeller L, Görges R, Janssen O E, Mann K. Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma.  Exp Clin Endocrinol Diabetes. 2002;  110 403-407
    Thieme ConnectPubMedSearch in Google Scholar
  • 45 Schmid K W, Sheu S Y, Görges R, Ensinger C, Tötsch M. Tumoren der Schilddrüse.  Pathologe. 2003;  24 357-372
    CrossrefPubMedSearch in Google Scholar
  • 46 Sheu S Y, Görges R, Schmid K W. Hyperplasien der Schilddrüse.  Pathologe. 2003;  24 348-356
    CrossrefPubMedSearch in Google Scholar
  • 47 Tommasi M, Brocchi A, Cappellini A, Raspanti S, Mannelli M. False serum calcitonin high levels using a non-competitive two-site IRMA.  J Endocrinol Invest. 2001;  24 356-360
    PubMedSearch in Google Scholar
  • 48 Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma.  World J Surg. 2004;  28 1271-1274
    CrossrefPubMedSearch in Google Scholar
  • 49 Vitale G, Ciccarelli A, Caraglia M, Galderisi M, Rossi R, Del Prete S, Abbruzzese A, Lupoli G. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin.  Clin Chem. 2002;  48 1505-1510
    PubMedSearch in Google Scholar
  • 50 Zaidi M, Inzerillo A M, Moonga B S, Bevis P J, Huang C L. Forty years of calcitonin - where are we now? A tribute to the work of Iain Macintyre, FRS.  Bone. 2002;  30 655-663
    CrossrefPubMedSearch in Google Scholar
  • 51 Zwermann O, Piepkorn B, Engelbach M, Beyer J, Kann P. Abnormal pentagastrin response in a patient with pseudohypoparathyroidism.  Exp Clin Endocrinol Diabetes. 2002;  110 86-91
    Thieme ConnectPubMedSearch in Google Scholar

Dr. med. Rainer Görges

Gemeinschaftspraxis für Nuklearmedizin

Sonnenwall 64

47051 Duisburg

Phone: +49/2 03/29 94 94

Email: rainer.goerges@uni-essen.de